IL288982A - Macrocyclic kinase inhibitor polymorphs - Google Patents

Macrocyclic kinase inhibitor polymorphs

Info

Publication number
IL288982A
IL288982A IL288982A IL28898221A IL288982A IL 288982 A IL288982 A IL 288982A IL 288982 A IL288982 A IL 288982A IL 28898221 A IL28898221 A IL 28898221A IL 288982 A IL288982 A IL 288982A
Authority
IL
Israel
Prior art keywords
polymorphs
kinase inhibitor
macrocyclic kinase
macrocyclic
inhibitor
Prior art date
Application number
IL288982A
Other languages
English (en)
Hebrew (he)
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of IL288982A publication Critical patent/IL288982A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL288982A 2019-06-19 2021-12-14 Macrocyclic kinase inhibitor polymorphs IL288982A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US202063036102P 2020-06-08 2020-06-08
PCT/US2020/037892 WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Publications (1)

Publication Number Publication Date
IL288982A true IL288982A (en) 2022-02-01

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288982A IL288982A (en) 2019-06-19 2021-12-14 Macrocyclic kinase inhibitor polymorphs

Country Status (15)

Country Link
US (1) US20220411439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986413A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537385A (cg-RX-API-DMAC7.html)
KR (1) KR20220046549A (cg-RX-API-DMAC7.html)
CN (1) CN114025765A (cg-RX-API-DMAC7.html)
AU (1) AU2020294627A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143043A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000405A2 (cg-RX-API-DMAC7.html)
IL (1) IL288982A (cg-RX-API-DMAC7.html)
MX (1) MX2021015756A (cg-RX-API-DMAC7.html)
PE (1) PE20220135A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553174A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115090A (cg-RX-API-DMAC7.html)
WO (1) WO2020257169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CA3069554A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
RS63787B1 (sr) * 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti

Also Published As

Publication number Publication date
PH12021553174A1 (en) 2022-08-01
WO2020257169A1 (en) 2020-12-24
MX2021015756A (es) 2022-01-27
AU2020294627A1 (en) 2022-02-17
PE20220135A1 (es) 2022-01-27
JP2022537385A (ja) 2022-08-25
BR112021025786A2 (pt) 2022-02-01
KR20220046549A (ko) 2022-04-14
CA3143043A1 (en) 2020-12-24
TW202115090A (zh) 2021-04-16
EP3986413A4 (en) 2023-06-14
CN114025765A (zh) 2022-02-08
CO2022000405A2 (es) 2022-04-29
US20220411439A1 (en) 2022-12-29
EP3986413A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
IL292644B1 (en) RAS inhibitors
IL286102A (en) macrocyclic compounds
EP3783000A4 (en) MACROCYCLIC KINASE INHIBITOR
GB201914860D0 (en) Inhibitor compounds
GB202008201D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
SMT202500291T1 (it) Forme solide di un promotore di spinogenesi
GB202013721D0 (en) New compounds
GB202015585D0 (en) New compounds
GB202004960D0 (en) Inhibitor compounds
GB201905328D0 (en) Inhibitor compounds
GB202110373D0 (en) Inhibitor compounds
GB201917867D0 (en) Polymorphs
IL297684B1 (en) Processes for preparing a kinase inhibitor
IL285427A (en) Crystal forms of jak2 inhibitor
EP3986413A4 (en) POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR
IL284564A (en) Polymorphic forms of a modified quinoline-type bridged piperidine compound
HK40073322A (en) Polymorphs of a macrocyclic kinase inhibitor
IL291368A (en) Inhibits expression of methadherin
GB202117224D0 (en) Inhibitor compounds
GB202012969D0 (en) Inhibitor compounds
IL294503B1 (en) Polymorphs of Alfibrinnor
GB202112240D0 (en) Inhibitor compounds
GB202107325D0 (en) Inhibitor compounds
GB202104781D0 (en) Inhibitor compounds